Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

NCT02244242 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT02244242
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02244242 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia
Lead sponsor
Boehringer Ingelheim
Phase
Phase 4
Overall status
Completed
Start date
July 31, 1998
Completion date
Not reported
Enrollment
493 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostatic hyperplasia